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Abstract
Introduction: Effective treatment of reactive arthritis would ideally achieve both control of inflammation and
eradication of persisting arthritogenic pathogens. We use a model of experimental Chlamydia trachomatis-induced
arthritis (CtIA) to evaluate the effectiveness of nafamostat mesilate (NM), a serine protease inhibitor with
complement-modifying effects and anticoagulant properties. To date clinical use of NM has largely been in Asia
and has been primarily confined to inflammatory states such as pancreatitis.
Methods: In vitro studies examined inhibition of Chlamydia proliferation using fibroblast cell lines as targets and
phase contrast microscopy. In vivo studies used an established protocol, experimental CtIA, induced in Lewis rats
by injection of synoviocyte-packaged C. trachomatis. NM was dissolved in water and administered by daily
intraperitoneal injection at a dose of 10 mg/kg beginning the day prior to the administration of Chlamydia.
Readouts in vivo included (i) joint swelling, (ii) histopathology scoring of severity of arthritis, (iii) host clearance of
the pathogen (by ELISA, the IDEIA PCE Chlamydia).
Results: NM exerted a dose-dependent inhibition of chlamydial proliferation in vitro. Without NM, the mean
number of inclusion bodies (IB) per well was 17,886 (± 1415). At 5 μg/mL NM, there were 8,490 (± 756) IB, at 25
μg/mL NM there were 35 IB and at 50 μg/mL NM no IB was observed. Chlamydial antigens in each well along the
concentration gradient were assayed by ELISA, demonstrating that at 25 μg/mL NM inhibition of Chlamydia was
almost complete. In the experimental arthritis model, joint swelling was significantly reduced with NM treatment:
average joint width for the NM-treated animals was 8.55 mm (s.d. ± 0.6578, n = 10) versus 11.18 mm (s.d. ± 0.5672,
n = 10) in controls (P < 0.001). Histopathology scoring indicated that NM resulted in a marked attenuation of the
inflammatory infiltration and joint damage: mean pathology score in NM-treated animals was 10.9 (± 2.45, n = 11)
versus 15.9 (± 1.45, n = 10) in controls (P < 0.0001). With respect to persistence of Chlamydia within the synovial
tissues, NM treatment was accompanied by a reduction in the microbial load in the joint: mean optical density (O.
D.) for ELISA with NM treatment was 0.05 (± 0.02, n = 4) versus 0.18 (± 0.05, n = 4) in controls (P < 0.001).
Conclusions: NM is a protease inhibitor not previously recognized to possess antimicrobial properties. The present
study demonstrates for the first time that NM exerts significant impact on C. trachomatis-induced arthritis and
suggests that such approaches may prove clinically useful in chronic reactive arthritis.
Introduction
The pathogenesis of reactive arthritis triggered by a
Chlamydia trachomatis infection has remained difficult
to define in the clinical setting [1]. We have established
a model of C. trachomatis-induced arthritis (CtIA) in
rats in which live Chlamydia was grown up in carrier
synovial fibroblasts and then injected directly into the
knee joints of rats [2]. We have defined the importance
of the cytokine profile in the development of CtIA [3]
and have also addressed the role of complement in the
resulting joint inflammatory process. To this end we
attempted to modify joint inflammation by administrat-
ing cobra venom factor to decomplement the animals
but no significant effect was seen. In our search for
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other complement-modifying agents, we have examined
a synthetic compound, nafamostat mesylate (NM) for its
effect on CtIA. NM, formerly known by the name FUT-
175, is a serine protease inhibitor that has been used
clinically in Asia, mainly Japan, as an anti-inflammatory
agent [4,5]. It is generally well tolerated although rare
occurrences of allergic reactions, hyperkalemia and
hemolysis have been reported. It has been used for its
complement-modifying effect and anticoagulant proper-
ties in the treatment of pancreatitis and disseminated
intravascular coagulation. To date there are no data
addressing the antimicrobial effects of NM, nor its effect
on reactive arthritis.
Materials and methods
Rats
Eight-week old male Lewis rats were purchased from
Harlan Laboratories (Indianapolis, IN, USA). They were
maintained in microisolators under specific pathogen-
free conditions in the animal care facility of the Toronto
Western Hospital, University Health Network. All stu-
dies were conducted with the approval of the Animal
Care Committee of the University Health Network.
Induction of arthritis
Arthritis was induced in the rats by the intra-articular
injection of live Chlamydia packaged in Lewis rat syno-
vial fibroblasts as previously described [2,3]. Briefly, C.
trachomatis serotype L2 was inoculated into monolayers
of the fibroblast lines in culture. After overnight incuba-
tion, the cells containing chlamydia were harvested and
injected into the knee joint of each rat at 5 × 105 colony
forming units (CFU)/joint. Rats were assessed on a daily
basis and then sacrificed four days after injection. At
necropsy, their knee joints were either processed for his-
topathology or for quantitation of intra-articular
Chlamydia.
Histopathology evaluation
For histology evaluations, joints were fixed in formalin.
They were measured with a caliper and then decalcified
as described previously [2,3]. They were sectioned and
stained with H & E. Sections were evaluated and scored
according to the system mentioned by us before.
Quantitation of Chlamydia in synovial tissues
We have adapted a clinical use ELISA kit, the IDEIA
PCE Chlamydia from OXOID-Dako (Basingstoke,, UK)
for the quantitation of Chlamydia in tissues [6]. Syno-
vial tissues from the joints were carefully dissected out
and homogenized. They were suspended in the trans-
portation medium provided by the ELISA kit in a fash-
ion as to normalize samples to the same wet weight per
volume. All samples were frozen and stored at -70°C
until assayed.
Treatment of rats
NM was purchased from Sigma (St. Louis, MO, USA).
The treatment scheme of Li et al. [7] for mice was fol-
lowed. Daily intraperitoneal injections at a dose of 10
mg/kg body weight were made. NM was dissolved fresh
in water each day just before use and then filtered steri-
lized before injection. The animals were briefly anesthe-
tized with Isofurane (Zenoca Pharma, Missisauga, Ont.,
Canada), weighed and then the precise amount injected
intraperitoneally. The injection schedule began on the
day before Chlamydia infection, and then on a daily
basis until the rats were sacrificed. Sterile water was
injected into the untreated control rats.
In vitro inhibition of Chlamydia proliferation
Lewis rat synovial fibroblast monolayers were set up on
six well tissue culture plates. One hour prior to inocula-
tion with Chlamydia, NM was added to the wells to
give a range of concentrations from 0 to 200 μg/mL in
duplicate wells. One hour after exposure to NM, the
monolayers were infected at 105 CFU/well. The plates
were spun down at 2 000 × G for 20 minutes to impact
the bacteria onto the cells. Thereafter, plates were incu-
bated at 37°C in a 5% CO2 incubator for 24 hours.
At the end of the incubation period, the monolayers
were examined under phase contrast microscopy for
Chlamydia inclusion bodies. Individual wells were har-
vested using cell scrapers and the contents frozen at
-70°C until assayed.
The above IDEIA PCE Chlamydia kit from OXOID-
Dako was also used for the quantitation of Chlamydia
growth. Since the read out for this ELISA was in O.D.,
in order to combine different experimental runs, percent
inhibition was calculated. The O.D. values from wells
without NM was set at 0% inhibition.
The percentage difference from test wells with
decreased O.D. values was calculated as percent
inhibition.
Results
In vitro inhibition of Chlamydia proliferation
Twenty four hour after fibroblast monolayers were
inoculated with 105 CFU/well of Chlamydia, large inclu-
sion bodies could be seen under phase contrast micro-
scopy within the majority of the cells. When NM was
introduced into the culture media, obvious effects could
be observed at 5 μg/mL concentration. The sizes of the
inclusion bodies became more variable and smaller ones
could be seen (Figure 1). With increasing concentrations
of NM the number of inclusions decreased and also
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became smaller. At 50 μg/mL and above, no inclusion
bodies could be found.
Under phase contrast microscopy, the number of
inclusion bodies in 100 high-power (40x) fields per well
in duplicate wells for each NM concentration were care-
fully enumerated. Results are plotted in Figure 2 which
represents data averaged from three separate experi-
ments. Without NM in the media, the average number
of inclusion bodies per well was 17,886 (± 1415). At 5
μg/mL, there were 8,490 (± 756) inclusions. At 25 μg/
mL 35 inclusions were found and no inclusion bodies
were observed at 50 μg/mL.
The chlamydial antigens in each well were assayed by
ELISA along the concentration gradient (Figure 3).
Results are expressed as the average percent inhibition
of three separate experiments with duplicate wells for
each concentration. It can be seen that NM is a very
powerful inhibitor of Chlamydia proliferation. At 25 μg/
mL inhibition was almost complete. This mirrored the
inclusion body counts above.
Chlamydia induced arthritis in rats
As expected from our model of CtIA, the non-treated con-
trol rats began to experience symptoms of joint inflamma-
tion beginning on the second day after intra-articular
infection with synoviocyte-packaged Chlamydia. By the
end of the experiment four days later, all the injected
joints were severely swollen. Animals experienced gradual
weight lost for the period of the experiment beginning on
Day 3 (Figure 4). On the other hand, the body weights of
similarly infected rats receiving daily treatments with NM
remained constant. The infected knee joints of these trea-
ted rats only experienced minimal swelling. At necropsy,
Chlamydia-infected joints of the rats were measured. The
average lateral width of the infected joints for the NM
treated animals was 8.55 mm (sd ± 0.6578, n = 10) while
that of the untreated control rats was significantly larger,
11.18 mm (sd ± 0.5672, n = 10) (P < 0.001).
Histopathology
The knee joints of untreated control rats all had severe
inflammatory changes with heavy infiltration of
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 D 
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Figure 1 Phase contrast photomicrographs of fibroblasts in culture, inoculated with chlamydia for 24 hours. Panel A. No NM added,
cells filled with large inclusion bodies. Panel B. 5 μg/mL of NM added, variations of inclusion sizes seen. Panel C. 10 μg/mL of NM added,
inclusions are much smaller. Panel D. 50 μg/mL of NM added, no inclusion bodies present. NM, nafamostat mesylate.
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leukocytes, predominately neutrophils, consistent with
our established experimental model (Figure 5). Soft
synovial tissues were heavily hypertrophic with foci and
necrosis, and there were extensive erosive changes. Most
of the cartilage tissues showed structural damage with
active panus formation. Panus could be seen invading
through into the bone marrow spaces. Using the Yang-
Hamilton grading scale, control knees had a mean score
of 15.9 (± 1.45, n = 10). In contrast, infected knee joints
from NM-treated rats showed much milder histopathol-
ogy. The leukocyte infiltrations were moderate and the
majority of the cells were mononuclear in nature. In
areas where the infiltration is light, synovial fatty tissues
could be seen. The synovial spaces were clearly defined
and there were only minor erosive changes. The average
Yang-Hamilton score for the test group is only 10.9 (±
2.45, n = 11). The difference between test and control
scores is very significant at 9.79 × 10-6.
Quantitation of Chlamydia in synovial tissues
The amounts of chlamydial antigen within the synovial
tissues of the infected knee joints were assayed by
ELISA. As shown in Figure 6, it is obvious that there is
significantly more Chlamydia in the synovial tissues of
the non-treated control knees than in the NM treated
joints. The mean O.D. values for the controls is 0.18 (±
0.05, n = 4) and for the NM-treated knees is 0.05 (±
0.02, n = 4). The difference is significant (P < 0.001).
Discussion
Among the spondyloarthropathies, the role of infec-
tion as a triggering factor is best established in reac-
tive arthritis (ReA) in which a sterile synovitis follows
an extraarticular infection. ReA occupies the concep-
tual ground somewhere between septic arthritis and
the classic autoimmune joint diseases such as RA [8].
Studies in ReA indicate that about 50% of such cases
can be attributed to a specific pathogen by a combina-
tion of culture and serology, the predominant organ-
isms being Salmonella, Yersinia and Chlamydia. It has
increasingly been recognized that post-viral arthritis
also constitutes an important subset of ReA. C. tra-
chomatis has the strongest and most direct evidence
for induction of ReA, with ReA occurring in 4% to
15% of those with chlamydial infections. Recent stu-
dies have demonstrated that current estimates for pre-
valence are likely underestimated as more than 60% of
undifferentiated Spondyloarthritis represents post-
Chlamydia ReA [9]. ReA is the paradigm of a rheu-
matic disease which reflects a dynamic interface
between environmental triggers and genetic suscept-
ibility. The fundamental distinctions between inflam-
matory joint disease as being autoimmune,
autoinflammatory, or septic in nature are highlighted
by the example of ReA [10].
NM is a serine protease inhibitor used clinically as an
anti-inflammatory. As a protease inhibitor, it is effective
in neutralizing the enzymatic activities of activated com-
plement components such as C1r, C1s, C3 and C5 con-
vertases [4,7,11-15]. It is also effective in inhibiting
elements in the alternate pathway such as Factors B and
D [11,13,14]. Similarly it is able to counter the activation
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Figure 2 The number of inclusion bodies decreased with
increasing NM concentrations. Under phase contrast microscopy,
the number of inclusion bodies in 100 high power (40x) fields per
well in duplicate wells for each NM concentration were numerated.
Results represent data averaged from three separate experiments.
NM, nafamostat mesylate.
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Figure 3 Inhibition curve of chlamydia proliferation by ELISA.
The chlamydial antigens in each well along the concentration
gradient were assayed by ELISA. Results are the average percent
inhibitions of three experiments with duplicate wells for each
concentration. ELISA, enzyme-linked immunosorbent assay; NM,
nafamostat mesylate.
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Figure 4 Weight lost experienced by untreated control rats (n = 10) during the experimental period as compared to minimal change
in the NM-treated rats (n = 10). N, number; NM, nafamostat mesylate.
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Figure 5 H & E sections of Chlamydia-injected knee joints. Panel A and B knee joints of NM-treated rats. Panel C and D knee joints of non-
treated controls. In Panels A and B, there are moderate infiltrations of inflammatory cells into the synovium. However, the synovial space is clear
and a considerable amount of the fatty tissues remains. The cartilage surfaces are mostly intact. On the other hand, in Panels C and D,
inflammation is extensive, the whole architecture of the joints was destroyed. Cartilage tissues had been totally eroded away and the invading
panus has entered the bone marrow space. Panel D also shows an area of early focus of necrosis. Original photomicrographs taken at 10×
magnification. NM, nafamostat mesylate.
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of key molecules in the coagulation cascade such as
thrombin and plasmin [14,16,17].
As an anti-inflammatory agent NM appears to prevent
granulocyte and phagocytic cell accumulations into
damaged tissues [11,12,14]. Immunologically, NM is also
known to suppress the production of cytokines IFNg,
TNF, IL17, IL4, IL5, IL6 and IL13 [7,16,17]. NM has
also been suggested as an anti-tumor agent since it
interferes with NF-B activation in cancer cell lines [18]
and in experimental rodent models [19].
Because of its broad range of actions as a protease
inhibitor, NM has been used experimentally in diverse
settings. Ishizak et al. [12] used NM on a model of mur-
ine allergy while Hagiwara et al. [17] used it to prevent
lung injury induced by LPS. Bonte et al. [11] and
Schwertz et al. [14] used NM to reduce cardiac injury
following experimental ischemia. Miyagi et al. [16]
reported a good outcome in experimental liver trans-
plant. Promising results were also reported in a rodent
experimental autoimmune encephalomyelitis model [7]
as well as in a rabbit model of autoimmune Guillain-
Barre syndrome [13]. NM has also been used to treat
adjuvant arthritis in rats to reduce the severity of the
arthritis [15]. Other than this early report in adjuvant
arthritis, the effect of NM in other types of arthritis has
not been evaluated.
Our data provide the first evidence that NM has
important antimicrobial properties. This could have
important implications for treatment options for clinical
Chlamydia-induced arthritis. At present the treatment
options are few [1]. There has recently been completed
a randomized, placebo-controlled study of combination
antibiotics for chronic Chlamydia-induced arthritis [20].
This has created renewed interest in examining agents
that might have both anti-inflammatory and antimicro-
bial effects. Future studies will address time kinetics of
different schedules of NM in the experimental model.
Our findings in the experimental model indicate that
NM would be an appealing candidate for such a thera-
peutic indication, and would be worthy of further inves-
tigation in this regard.
Conclusions
NM is a protease inhibitor not previously recognized to
possess antimicrobial properties. The present study
demonstrates for the first time that NM exerts a signifi-
cant impact on C. trachomatis-induced arthritis. These
findings suggest that such an approach may prove clini-
cally useful in chronic reactive arthritis.
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